Immune System News and Research

RSS

Dartmouth’s professor shares news of DAR-901 TB vaccine development

Tuberculosis (TB) is second only to HIV/AIDS as the greatest killer worldwide attributable to a single infectious agent, according to the World Health Organization (WHO). With 8.8 million cases in 2010 and 95 percent of TB deaths occurring in low- and middle-income countries, the disease continues to be a major public health problem in the developing world. In a July address to the International Union Against Tuberculosis and Lung Disease, Dartmouth's C. Fordham (Ford) von Reyn shared news of a promising vaccine in the works.

24 Aug 2012

Diabetes journal reports results from novel experimental therapy

Results from a novel experimental therapy for Type 1 diabetes that boosts parts of the healthy immune system are reported today in the scientific journal Diabetes.

24 Aug 2012

Researchers discover new way to disarm harmful bacteria

Rather than trying to kill bacteria outright with drugs, Université de Montréal researchers have discovered a way to disarm bacteria that may allow the body's own defense mechanisms to destroy them. "To understand this strategy one could imagine harmful bacteria being like Darth Vader, and the anti-virulence drug would take away his armor and lightsaber," explained Dr. Christian Baron, the study's lead author and Professor at the Department of Biochemistry.

24 Aug 2012

New disease causes AIDS-like symptoms but not spread through virus

"Researchers have identified a mysterious new disease that has left scores of people in Asia and some in the United States with AIDS-like symptoms even though they are not infected with HIV," the Associated Press reports.

24 Aug 2012

The Wistar Institute, MSKCC partner to publish first annotated atlas of Epstein-Barr virus genome

Researchers from The Wistar Institute and Memorial Sloan-Kettering Cancer Center (MSKCC) have teamed to publish the first annotated atlas of the Epstein-Barr virus genome, creating the most comprehensive study of how the viral genome interacts with its human host during a latent infection. Epstein-Barr virus (EBV), which is thought to be responsible for one percent of all human cancers, establishes a latent infection in nearly 100 percent of infected adult humans.

24 Aug 2012

Scripps Research Institute scientist to uncover workings of the immune system

A team led by a scientist at The Scripps Research Institute has received a $22.5 million, five-year project renewal from the National Institutes of Health to uncover the workings of the immune system.

24 Aug 2012

Nanoparticle may bring great benefits to emergency treatment of brain-injury victims

A nanoparticle developed at Rice University and tested in collaboration with Baylor College of Medicine (BCM) may bring great benefits to the emergency treatment of brain-injury victims, even those with mild injuries.

24 Aug 2012

Influenza virus can change microRNA expression to control immune responses in human lung cells

When you are hit with the flu, you know it immediately -- fever, chills, sore throat, aching muscles, fatigue. This is your body mounting an immune response to the invading virus. But less is known about what is happening on the molecular level.

24 Aug 2012

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

Northwest Biotherapeutics announced today that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom, for the Company's 300-patient Phase III clinical trial of DCVax-L immune therapy for Glioblastoma multiforme brain cancer (GBM) to proceed in the U.K.

24 Aug 2012

Article describes immune-related adverse events with newly approved melanoma drug

An internationally recognized melanoma researcher at Moffitt Cancer Center and colleagues at the University of Kiel in Germany, including Axel Hauschild, M.D. and Katharina C. K-hler, M.D., have published an article in the current issue of The Journal of Clinical Oncology that describes immune-related adverse events for patients receiving either tremelimumab or ipilimumab, the latter a drug approved last year by the U.S. Food and Drug Administration for treating metastatic melanoma and other cancers.

23 Aug 2012

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical results in the journal Cancer Immunology Immunotherapy describing the development of a dendritic cell (DC) cancer vaccine with enhanced immunogenic potential.

23 Aug 2012

Aeras, IDRI announce start of first ID93 + GLA-SE Phase I trial for tuberculosis

Aeras and the Infectious Disease Research Institute (IDRI) announce today the start of the first clinical trial of IDRI's novel tuberculosis vaccine candidate, ID93 + GLA-SE.

23 Aug 2012

TREM-1 gene disrupts inflammatory process implicated in liver cancer

Researchers at the Georgia Health Sciences University Cancer Center have identified a gene that disrupts the inflammatory process implicated in liver cancer.

23 Aug 2012

RNA switches can better equip and regulate viruses for many therapeutic applications

Numerous viruses are used in the service of science today. They serve as gene taxis to transfer therapeutic genes into body cells or as therapeutic viruses targeted to infect and destroy cancer cells. For such applications, the viruses are often equipped with additional genes, such as for immune mediators or for proteins inducing programmed cell death. However, these gene products can harm the body if they are released at the wrong moment or at excessive levels.

22 Aug 2012

UC San Diego, iSAEC partner to study genetics of drug induced renal injury

The International Serious Adverse Events Consortium (iSAEC) announced today it will collaborate with the University of California, San Diego School of Medicine and UC San Diego Skaggs School of Pharmacy and Pharmaceutical Science to research the genetics of drug induced renal injury (DIRI).

22 Aug 2012

Immune System News and Research

Dartmouth’s professor shares news of DAR-901 TB vaccine development

Diabetes journal reports results from novel experimental therapy

Researchers discover new way to disarm harmful bacteria

New disease causes AIDS-like symptoms but not spread through virus

The Wistar Institute, MSKCC partner to publish first annotated atlas of Epstein-Barr virus genome

Scripps Research Institute scientist to uncover workings of the immune system

Nanoparticle may bring great benefits to emergency treatment of brain-injury victims

Influenza virus can change microRNA expression to control immune responses in human lung cells

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

Article describes immune-related adverse events with newly approved melanoma drug

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Aeras, IDRI announce start of first ID93 + GLA-SE Phase I trial for tuberculosis

TREM-1 gene disrupts inflammatory process implicated in liver cancer

RNA switches can better equip and regulate viruses for many therapeutic applications

UC San Diego, iSAEC partner to study genetics of drug induced renal injury

Study identifies certain small molecule chemicals that can disrupt quorum sensing in A. baumanni

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

Study on sea lamprey may indicate how potentially deleterious genes can be controlled

Stem-cell therapy holds promise for postinjury arthritis prevention

New silicon chips help identify patients with lupus

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News